Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Current Leases (2021 - 2025)

Historic Current Leases for Sutro Biopharma (STRO) over the last 5 years, with Q3 2025 value amounting to $8.0 million.

  • Sutro Biopharma's Current Leases rose 1050.95% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 1050.95%. This contributed to the annual value of $7.5 million for FY2024, which is 1651.09% up from last year.
  • Per Sutro Biopharma's latest filing, its Current Leases stood at $8.0 million for Q3 2025, which was up 1050.95% from $8.1 million recorded in Q2 2025.
  • Sutro Biopharma's Current Leases' 5-year high stood at $8.1 million during Q2 2025, with a 5-year trough of $1.0 million in Q4 2021.
  • Its 5-year average for Current Leases is $5.2 million, with a median of $6.2 million in 2023.
  • Its Current Leases has fluctuated over the past 5 years, first surged by 42982.14% in 2023, then surged by 1050.95% in 2025.
  • Over the past 5 years, Sutro Biopharma's Current Leases (Quarter) stood at $1.0 million in 2021, then soared by 342.14% to $4.6 million in 2022, then soared by 40.02% to $6.4 million in 2023, then increased by 16.51% to $7.5 million in 2024, then grew by 6.42% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $8.1 million for Q2 2025, and $7.8 million during Q1 2025.